The estimated Net Worth of John G Mc Hutchison is at least $7.77 Million dollars as of 23 May 2024. John Hutchison owns over 2,117 units of Assembly Biosciences Inc stock worth over $332,028 and over the last 7 years he sold ASMB stock worth over $431,479. In addition, he makes $7,007,210 as President, Chief Executive Officer, and Director at Assembly Biosciences Inc.
John has made over 8 trades of the Assembly Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,117 units of ASMB stock worth $31,607 on 23 May 2024.
The largest trade he's ever made was selling 25,972 units of Assembly Biosciences Inc stock on 22 May 2023 worth over $27,011. On average, John trades about 4,271 units every 69 days since 2018. As of 23 May 2024 he still owns at least 19,104 units of Assembly Biosciences Inc stock.
You can see the complete history of John Hutchison stock trades at the bottom of the page.
Dr. John G. McHutchison M.D. serves as President, Chief Executive Officer, Director of the Company., is President, Chief Executive Officer, Director of the Company. Prior to joining us, Dr. McHutchison was the Chief Scientific Officer and Head of Research and Development of Gilead. Prior to joining Gilead in 2010, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke University, Dr. McHutchison spent nearly ten years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. In June 2018, Dr. McHutchison was appointed an Officer of the Order of Australia in recognition of his distinguished service to medical research in gastroenterology and hepatology. Dr. McHutchison has undergraduate degrees in medicine and surgery from the University of Melbourne in Australia and completed his residency in internal medicine and fellowship in gastroenterology at the Royal Melbourne Hospital. He is a member of the Royal Australasian College of Physicians.
As the President, Chief Executive Officer, and Director of Assembly Biosciences Inc, the total compensation of John McHutchison at Assembly Biosciences Inc is $7,007,210. There are no executives at Assembly Biosciences Inc getting paid more.
John McHutchison is 62, he's been the President, Chief Executive Officer, and Director of Assembly Biosciences Inc since 2019. There are 8 older and 10 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
John's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak, and Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
Assembly Biosciences Inc executives and other stock owners filed with the SEC include: